Results 141 to 150 of about 2,583,576 (275)

ISUOG/ESGO Consensus Statement on ultrasound‐guided biopsy in gynecological oncology

Ultrasound in Obstetrics &Gynecology, Volume 65, Issue 4, Page 517-535, April 2025.
ABSTRACT The International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) with the European Society of Gynaecological Oncology (ESGO) jointly developed clinically relevant and evidence‐based statements on performing ultrasound‐guided biopsies in gynecological oncology.
D. Fischerova, F. Planchamp, J. L. Alcázar, P. Dundr, E. Epstein, A. Felix, F. Frühauf, G. Garganese, I. Salvesen Haldorsen, D. Jurkovic, R. Kocian, D. Lengyel, F. Mascilini, A. Stepanyan, M. Stukan, S. Timmerman, T. Vanassche, Z. Yuan Ng, U. Scovazzi   +18 more
wiley   +1 more source

Collected Experience of the Pennsylvania Hemophilia Program [PDF]

, 1977
S.S. Shapiro, M.E. Eyster, J. Lewis
openalex   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review

British Journal of Pharmacology, Volume 182, Issue 7, Page 1416-1445, April 2025.
Abstract In the past year, the European Medicines Agency (EMA), the Food and Drug Administration (FDA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) authorised 53 novel drugs. While the 2024 harvest is not as rich as in 2023, when 70 new chemical entities were approved, the number of ‘orphan’ drug authorisations in 2024 (21) is ...
Stavros Topouzis, Andreas Papapetropoulos, Steve P. H. Alexander, Miriam Cortese‐Krott, Dave A. Kendall, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Mauro M. Teixeira, Nathalie Vergnolle, Xin Wang, Péter Ferdinandy   +16 more
wiley   +1 more source

Defibrination Syndrome Developed after Replacement Therapy with PPSB in a Case of Hemophilia B. [PDF]

, 1977
Mutsuyoshi Kazama, H Iwakura, Masaru Nakajima, M. Abe, Tetsuya Abe   +4 more
openalex   +1 more source

Identification of Risk Factors and Predictive Indicators for Tigecycline‐Associated Hypofibrinogenemia

Clinical and Translational Science, Volume 18, Issue 4, April 2025.
ABSTRACT To investigate the prevalence, clinical manifestations, and risk factors of hypofibrinogenemia after tigecycline use, which can disrupt coagulation and potentially hinder antimicrobial therapy. This observational study was conducted from January to December 2021 at a tertiary general hospital in China.
Xiaohui Liu, Xuefeng Yuan, Long Wen, Xin Tan, Qian Sui, Jiheng Liu   +5 more
wiley   +1 more source

The Edges of Clinical Pharmacology: A Narrative Review on Religious and Sociocultural Influences in Drug Management

Clinical and Translational Science, Volume 18, Issue 4, April 2025.
ABSTRACT Scientific advancements in pharmacology have revolutionized disease management, significantly enhancing global health. Innovations like biological therapies and mRNA vaccines underscore the field's capacity to address complex conditions and global crises.
Salvatore Di Maria, Alessio Provenzani
wiley   +1 more source

The Utility of Total Thrombus‐Formation Analysis System (T‐TAS) in the Thrombosis and Hemostasis Field: A Scoping Review

International Journal of Laboratory Hematology, Volume 47, Issue 2, Page 201-211, April 2025.
ABSTRACT Background A wide variety of laboratory hemostasis tests is available, but the majority is plasma‐based, static and unable to assess platelet function and fibrin formation simultaneously. The Total Thrombus‐Formation Analysis System (T‐TAS) is a microchip‐based flow chamber system that simulates in vivo conditions for evaluating whole blood ...
H. Mansouritorghabeh, A. Monard, F. Heubel‐Moenen, J. Leentjens, A. Stroobants, Y. Henskens   +5 more
wiley   +1 more source

The Role of the Consumer-Patient in the Growth of a Comprehensive Hemophilia Care Unit [PDF]

, 1977
Dorothy Child, John Kopicki, David VanHarlingen   +2 more
openalex   +1 more source

Thrombin Generation Assay to Support Hematologists in the Era of New Hemophilia Therapies

International Journal of Laboratory Hematology, Volume 47, Issue 2, Page 212-220, April 2025.
ABSTRACT Hematology laboratories have traditionally monitored hemophilia replacement therapy by measuring coagulation factors before and after infusion. However, new drugs that do not rely on the replacement of the deficient factor require new approaches to laboratory monitoring, as factor VIII (FVIII) or factor IX (FIX) assays are no longer adequate ...
Laurie Josset, Hamdi Rezigue, Yesim Dargaud   +2 more
wiley   +1 more source

Nonneutralizing antibodies in Nordic persons with moderate hemophilia A and B (the MoHem study)

Research and Practice in Thrombosis and Haemostasis
Background: The impact of nonneutralizing antibodies (NNAs) in moderate hemophilia is elusive. Objectives: To explore the presence of NNAs in Nordic persons with moderate hemophilia A (MHA) and B (MHB) in relation to treatment modality, clinical outcome,
Ragnhild J. Måseide, MD, PhD, Erik Berntorp, MD, PhD, Jan Astermark, MD, PhD, Anna Olsson, MD, PhD, Maria Bruzelius, MD, PhD, Tony Frisk, MD, PhD, Vuokko Nummi, MD, PhD, Riitta Lassila, MD, PhD, Karin Strandberg, MD, PhD, Geir E. Tjønnfjord, MD, PhD, Pål A. Holme, MD, PhD   +10 more
doaj